DoW Kidney Cancer, Concept Award

The Kidney Cancer Research Program Concept Award is administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs, a federal funding initiative designed to support innovative biomedical research that addresses critical health challenges affecting service members, veterans, and the broader public. This specific funding opportunity focuses on advancing research in kidney cancer, a disease area identified by Congress as requiring targeted investment. The program emphasizes high-impact, high-risk scientific exploration and seeks to stimulate novel ideas that could lead to breakthroughs in understanding, diagnosing, and treating kidney cancer. The Concept Award mechanism has been in place since 2017 and is intended to support early-stage, exploratory research rather than incremental advancements. The primary purpose of this award is to fund highly innovative and untested concepts that have the potential to open entirely new avenues of investigation in kidney cancer research. Applicants are required to propose novel hypotheses or approaches that significantly depart from existing paradigms. Importantly, preliminary data are not allowed, reinforcing the program’s focus on early-stage conceptual innovation. The research must align with at least one of the program’s focus areas, which include advancing biological understanding, developing new therapeutic strategies, improving patient care, and addressing disparities in outcomes. Projects may span basic science, translational research, or clinical relevance, but clinical trials themselves are explicitly prohibited. Funding for this opportunity is limited, with approximately seven awards anticipated and a total program allocation of about 840000 dollars. Each award is capped at 120000 dollars in total costs for a maximum performance period of one year. Allowable costs include research-related expenses and limited travel for collaboration or dissemination of findings, while certain costs such as clinical trial activities are not permitted. There is no requirement for cost sharing or matching funds. All awarded funds must be used within the defined federal funding period, and awards are expected to be finalized by September 30, 2027. Eligibility for the program is broad and inclusive. Both domestic and international organizations may apply, including for-profit and nonprofit entities, as well as public and private institutions. Individuals must apply through an eligible organization and must be at least at the level of a postdoctoral fellow or equivalent to serve as Principal Investigator. There are no restrictions based on citizenship or nationality. Each investigator may submit only one application to this funding opportunity. Awards are made to organizations rather than individuals, and applicants must ensure compliance with federal registration requirements, including active registrations in SAM.gov, eBRAP, and Grants.gov. The application process is structured as a two-step submission. First, applicants must submit a pre-application in the form of a Letter of Intent through the eBRAP system. This is followed by a full application submission through either Grants.gov or eBRAP, depending on the applicant type. The application must adhere to strict formatting and anonymity requirements due to the program’s double-blind peer review process. Applicants are prohibited from including identifying information about themselves or their institutions in key components of the proposal. Required materials include a project narrative, supporting documentation, statement of work, impact statement, innovation statement, and additional administrative forms. Applications undergo a two-tier review process consisting of peer review and programmatic review. Peer review evaluates the scientific merit based on innovation, impact, and research strategy, while programmatic review assesses alignment with program priorities and portfolio balance. Additional considerations include the feasibility of the research plan and the appropriateness of the budget. The review process is competitive, and funding decisions are influenced by both technical merit and strategic relevance to the program’s goals. Key deadlines for the current cycle include a pre-application submission deadline of July 28, 2026, and a full application deadline of August 11, 2026. Peer review is expected to occur in October 2026, followed by programmatic review in December 2026. Notifications of funding decisions are typically provided within several weeks after programmatic review. This funding opportunity is part of an annual federal appropriations cycle, indicating that similar opportunities are likely to recur in future years, although exact dates may vary.

Focus on highly innovative untested concepts; do not include preliminary data; strictly follow anonymization rules to avoid rejection